DIRECTORY
BIOTECH
Pharmaclient

   

Quick Click ! Monthly news Home-Site Menu-Site Contactexpress Faqs Legends Companies Events Environment Memories Home-Biotech

Abcys | AB Science | Adocia | Advicenne Pharma | Affichem | Agate Bioservices | Aisa Therapeutics | Alfact Innovation | Alizé Pharma | Ambiotis | Anaconda Pharma | Aptys Pharmaceuticals | Ariana Pharmaceuticals | Aterovax | Atlantic Bone Screen | Aureus Sciences | B Cell Design | BioAlliance Pharma | Biocortech | BioCydex | Biométhodes | Biom'up | BioProtein Technologies | BioQuanta | BioSystems International | BMSystems (Bio-Modeling) | Carmat | Cellectis | Cellial Technologies | CellProthera | CellVax | Cerenis Therapeutics | CliniGenetics | Covalab | Cytheris | Cytoo | DBV Technologies | Diaxonhit | DNA Therapeutics | Domain Therapeutics | Dynabio | Edelris | Endotis Pharma | Epixis | ERYtech Pharma | Eye Tech Care | Flamel Technologies | Fluofarma | GemacBio | Genepep | Genewave | Genfit | Genomic Vision | GenoSafe | GenoScience Pharma | Genoscreen | GenOway | Genticel | GTP Technology | Helios Biosciences | Hemarina | Hybrigenics | Hyphen BioMed | Imagene | ImmunId | Immutep | Imstar | In-Cell-Art | Indicia Biotechnology | InGen Biosciences | Innate Pharma | InnaVirVax | Innovative Health Diagnostics | IntegraGen | Ipsogen | I-Stem | Karcinolys | Keosys | MABlife | Magnisense | Mapreg | Mauna Kea Technologies | Medesis Pharma | Mellitech | Metabolys | MilleGen | Murigenetics | NanoBiotix | Neorphys | Neovacs | Netris-Pharma | Neuronax | NewVectys | NicOx | Nokad | Nosopharm | NovAliX | NovoCIB | Novotec | Obe Therapy | Oligovax | Oncodesign | OriBase Pharma | Oroxcell | Oxincell | Palumed | PharmaLeads | Pharnext | PhenoPro | Pherecydes Pharma | PolyIntell | Proteogenix | Protexel | PX'Therapeutics | Quantum Genomics | Rhenovia Pharma | ScarCell Therapeutics | Sisène Biotechnologies | Skuld-Tech | Stentys | Synapcell | Synprosis | Tc Land Expression | Theraclion | Theradiag | Theralpha | TheraVectys | Transgene | Trophos | TxCell | UROsphere | Vaxon Biotech | Vectalys | Vivalis | XenTech |

* RHENOVIA PHARMA *


 

2007 - Alsace
Mulhouse
www.rhenovia.com

 

Contract, Research
Key words: Alzheimer, Biosimulation, Computational neuroscience, Memory
Mission: to contribute to discover new medicines against Alzheimer's and other central nervous system (CNS) diseases, by developing breakthrough biosimulation platforms for memory and other CNS functions
Clients: Pharmaceutical industry, Biotechs
info@rhenovia.com

Age: 9 year(s)

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Personal venture |
Managing Dir.-CEO: Bischoff (Serge) [co-founder, born 1948, Ph.D. neuropharmacology, ex-Novartis]
Sc.Dir.-CSO: Baudry (Michel) [co-founder, born 1948, Eng. Ecole Polytechnique, Prof. engineering (Los Angeles), Ph.D.]
Oper.Dir.-COO: Faupel (Michel) [co-founder, ex-Novartis]
Fin.Dir.-CFO:
BusDev: George (Florian) [Ph.D. chemistry]
Financers (Hist.): privately owned, no outisde investors (registered capital 2007 = 0.126 M€)

Turnover (M€) : 0.092 (2009)
Total funding (M€) : 1.0
Last funding (M€) : 1.0
Focus : CNS
Position : Proof-of-Concept
Company confirm : none

 

History
DATEMILESTONETYPETIME
2012 .04 2nd round-financing : € 3.1 Million, by undisclosed investors to support new biosimulation drug discovery programs for Huntington Disease and Duchenne muscular dystrophies RFINB [4 years]
2012 .02 Set-up of Rhenovia Inc, based in the Greater Boston Area with offices in Cambridge, Massachusetts ORGC [4 years]
2011 .05 Partnering marketing agreement with Portmann Instruments for Rhenovia's biosimulation services in Switzerland LICOUT [4 years]
2011 .04 Partnering R&D agreement with Sodiaal-Candia for studying the nutritional and therapeutic value of milk and its derivatives R&D [3 years]
2010 .12 Partnering research collaborative project with AFM (Association Française des Myopathies) for 0.5 M€ over 2 years to support their simulation technology for diseases of the nervous system R&D [3 years]
2010 .07 Company headquarters move in new buildings, still in Mulhouse ORGL [3 years]
2010 .04 Partnering research collaborative project RHENEPI lead for 2.5 M€ over 3 years in order to develop a platform biosimulation of seizures (other partner Synapcell as CRO) R&D [2 years]
2009 .04 Financing (grant) : 1.6 M€ (2.3 MUS$), by state R&D institution NIH (USA) shared by Biomedical Engineering, LAS and Rhenovia, over 4 years RFIN [1 year]
2007 .05 Company founded by Serge Bischoff, Pr. Michel Baudry, Jan Kremers, and Michel Faupel ORGF [0 year]

Actualisation / Updating: 13-Dec-2012

   


Pharmaclient est le site-conseil de la Valorisation Client en Pharma...
Pour toute Mission, Inscription à la Pharmagalerie, Insertion dans la base Biotech, ou Question: CONTACT



© J.H. Huber, Pharmaclient 2001-2017. Pour retourner à la page d'accueil Biotech: BIENVENUE !       Haut de page : légende